Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.




Researchers To Present Additional Data On Soliris(R) (eculizumab) For The Treatment Of Patients With PNH At The ASH Annual Meeting

Sponsored by Internet Pharmacy - Indian Pharmacy, an online pharmacy supplies more than 600 quality generic medications, free prescription, worldwide shipping.

Canadian Pharmacy canada pharmacy

Related posts:

  1. Abbott To Present Data On Several Investigational Cancer Treatments At American Society Of Clinical Oncology Annual Meeting Abbott scientists and independent researchers will highlight the latest clinical trial data on four of Abbott’s investigational oncology compounds at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting,...
  2. USC Faculty Present Breakthrough Research At ASCO Annual Meeting Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American...
  3. Phase 3 Data On VIVUS’ Avanafil For Erectile Dysfunction To Be Featured At The AUA 2010 Annual Meeting VIVUS, Inc. (Nasdaq: VVUS) announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of erectile dysfunction (ED),...